OncoSec Medical Inc. Granted New Patent from China
SAN DIEGO, Sept. 5, 2012 /PRNewswire/ -- OncoSec Medical Inc. (OTCBB: ONCS), a company developing its advanced-stage ImmunoPulse and NeoPulse technologies to treat solid tumor cancers, received a new Method of Use and Device patent (Patent Application No. 200780014313.0, "Method and Device for Treating Microscopic Residual Tumors Remaining in Tissues Following Surgical Resection") for the OncoSec Medical System (OMS) electroporation device platform from the State Intellectual Property Office of the People's Republic of China. The issuance of this patent has the potential to expand OncoSec's commercial opportunities for minimally invasive and surgical procedures to treat solid tumors in a very large market such as China.
(Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO)
Punit Dhillon, OncoSec's President and CEO, commented, "The issuance of this patent is significant, because the Chinese authorities have given the company patent approval for our claims regarding the OMS electroporation device itself, as well as the method of use. These are broad claims, wherein OncoSec now has the ability to deliver various therapeutic agents through its electroporation device, including bleomycin and DNA IL-12, as well as to treat tumors with these agents following surgical resection. Thus, this patent will act as a part of the company's core strategy as we continue to develop and build our commercialization strategy in China, one of the largest emerging oncology markets."
Numerous research studies have concluded that cancer has now become a leading cause of mortality in China, representing 25 percent of all deaths in urban areas and 21 percent in rural areas. Moreover, cancer mortality in China has been increasing rapidly and continuously during the past three decades, which indicates a significant need for novel therapies.
ImmunoPulse and NeoPulse are investigational therapies being evaluated to reduce the rate of cancer recurrence while minimizing quality-of-life side effects. These therapeutic approaches, as potential adjuncts to surgery, involve injecting the tumor with an anti-cancer agent, followed by electroporation to open up the cell membrane, which helps significantly increase the uptake of the agent. This approach has been shown to selectively kill cancer cells that may exist in the neighboring tissue, which may result in a reduced rate of recurrence and has the potential to complement standard-of-care surgical procedures.
About OncoSec Medical Inc.
OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage ImmunoPulse and NeoPulse therapies to treat solid tumor cancers and metastatic disease. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec's core technology is based upon its proprietary use of an electroporation platform, the OncoSec Medical System (OMS), to dramatically enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at www.oncosec.com. Additional information may also be found at OncoSec's Facebook, Twitter, and LinkedIn sites.
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
SOURCE OncoSec Medical Incorporated